Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03726905
Other study ID # mcmsuaadd001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 30, 2018
Est. completion date December 30, 2020

Study information

Verified date November 2022
Source Lomonosov Moscow State University Medical Research and Educational Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to test the hypothesis that the physical rehabilitation starting with respiratory training followed by the aerobic exercises will have a more pronounced effect on clinical and functional indicators than the currently used physical rehabilitation based on aerobic training alone


Description:

Changes in the respiratory muscles play an important role in the pathophysiology of exercise intolerance in CHF patients. The weakness of the respiratory muscles leads to a decrease in the efficiency of breathing and the formation of a pathological type of breathing, in which the inhalation time is prolonged, and the expiration time is shortened. Patients with weak respiratory muscles have impaired functional status, as determined by peak oxygen consumption. The violation of the ratio of inspiratory time / to the total time of the respiratory cycle is associated with an increase in the activity of the sympathoadrenal system. The positive effect of respiratory muscle training on MIP, MEP, peak VО 2, VE, VE / VCO 2 slope, VE oscillation, rhythm variability, and quality of life parameters is shown. Decreased oxygenation of the respiratory muscles during intense physical exertion in patients with CHF may increase respiratory failure and provoke hyperactivation of the inspiratory metaboreflex, thereby aggravating exercise intolerance due to a decrease in muscular-muscular system perfusion due to redistribution of blood flow. In addition, it was shown that fatigue of the respiratory muscles increases the activity of the sympathetic nervous system and reduces blood flow in the muscles of the inactive limb due to adrenergic vasoconstriction. This response is most likely associated with metabolic stimulation of small afferent type III and IV fibers of the respiratory muscles, especially the diaphragm. Respiratory muscle training can minimize the effects of inspiration metaboreflex activation and prolong the duration of exercise. In addition, several studies have shown that the strength of the respiratory muscles in patients with HF correlates with central hemodynamic indices at rest, including cardiac output, mean pulmonary pressure and pulmonary vascular resistance. Several studies have shown that the mechanism that improves exercise tolerance in patients with HF after training the respiratory muscles is to increase the blood supply to the muscles of the limbs at rest and during exercise. Thus, the mechanisms of the effect of the weakness of the respiratory muscles on the pathogenesis of a decrease in the functional ability of patients are well studied. Both respiratory muscular and aerobic exercises of moderate effectiveness are recommended by leading medical communities as an effective means to improve the functional ability of patients, improve quality of life parameters, improve symptoms and reduce hospital admissions (level of evidence Level 1). At the same time, respiratory muscle training is recommended as the beginning of physical rehabilitation in patients with IV FC HF, and moderate-intensity aerobic training is recommended for patients with FC I-III FC. Also, in individual works abroad, the effects of respiratory muscle training on clinical CHF. However, according to the investigator's information, no studies have been carried out on the study of the method of functional training, including training of the respiratory muscles, as an obligatory initial stage of physical rehabilitation of patients with any functional class of HF.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 30, 2020
Est. primary completion date December 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Male and female patients aged 18 years and older (inclusive) - Patients with stable heart failure of the II-III functional class. - Signed patient informed consent to participate in the study. - Left ventricular ejection fraction =40%, confirmed by the results of EchoCG no more than 3 months before the start of the study. - Patients who can understand the objectives of this study and comply with the requirements of the Protocol. Exclusion Criteria: - • Heart failure I and VI functional class - Left ventricular ejection fraction> 41% or no confirmed data on the left ventricular EF. - Myocardial infarction, ACS, heart surgery, percutaneous coronary intervention, or coronary artery bypass surgery performed less than 3 months prior to randomization. - Unstable or refractory angina. - Pulmonary heart. - Constrictive pericarditis. - Hypertrophic cardiomyopathy. - Amyloid cardiomyopathy. - Syndrome of premature excitation of the ventricles. - The need for percutaneous coronary intervention or coronary bypass surgery in the near future. - Sinus node dysfunction syndrome. - The presence of a pacemaker. - The presence of diagnosed non-cardiac causes of CHF. - Any non-cardiac disease that reduces the expected duration to less than 2 years from the moment of randomization. - A stroke less than 1 month prior to randomization or a stroke with marked continuing neurological disorders less than 12 months before randomization - Orthopedic disorders that prevent physical training - COPD, Bronchial asthma. Another lung disease that can affect CSTP results - Significant impaired renal function (plasma creatinine 220 µmol / L or higher). - Significant abnormal liver function (increased ALT or AST more than 3 times relative to the upper limit of normal). - Acute coronary syndrome less than 3 months before randomization. - Obstructive or restrictive cardiomyopathy. - Acute myocarditis. - Hemodynamically significant organic lesions of valves requiring surgical intervention. - A history of heart transplantation or current waiting for a heart transplant. - Drug addiction, substance abuse, alcoholism, drug use in history. - Mental, physical and other reasons that do not allow to adequately assess their behavior and correctly fulfill the conditions of the study protocol. - A history of any significant, in the opinion of the physician-researcher, condition / disease or circumstances that prevent the inclusion in the study. - Inability / reluctance of the patient to provide signed informed consent to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
respiratory muscles training
4 weeks respiratory muscles training aimed on respiratory muscles endurance and lengthening expiration time
sham respiratory muscles training
4 weeks sham respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0
aerobic training
12 weeks treadmill walking

Locations

Country Name City State
Russian Federation Julia Begrambekova Moscow Moscow Region

Sponsors (2)

Lead Sponsor Collaborator
Lomonosov Moscow State University Medical Research and Educational Center Russian Heart Failure Society

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in health-related quality of life Minnesota Living with Heart Failure Questionnaire/ The quality of life between study groups and the change in quality of life over time between study groups. 4 weeks
Other Change in health-related quality of life Minnesota Living with Heart Failure Questionnaire. Assessed from baseline visit to 16 weeks follow-up visit.The quality of life between study groups and the change in quality of life over time between study groups using clinically accepted quality of life measures. MLHFQ 16 weeks
Other Anxiety and Depression Hospital Anxiety sand Depression Scale (HADS) The questionnaire comprises seven questions for anxiety and seven questions for depression.Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21. The cut off for both scales in 11. 4 weeks
Other Anxiety and Depression Hospital Anxiety sand Depression Scale (HADS) The questionnaire comprises seven questions for anxiety and seven questions for depression.Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21. The cut off for both scales in 11. 16 weeks
Primary Functional Capacity Change in Peak VO2 16 weeks
Secondary proBNP Change in concentration of NT- proBNP from baseline 4 weeks
Secondary proBNP Change in concentration of NT- proBNP from baseline 16 weeks
Secondary Respiratory muscle strength Change in maximal inspiratory and expiratory pressures (PImax and PEmax) from baseline 4 weeks
Secondary Respiratory muscle strength Change in maximal inspiratory and expiratory pressures (PImax and PEmax) from baseline 16 weeks
Secondary Neurohormone activity Difference between Active and Control groups in Angiotensin II (A II) concentration from baseline 4 weeks
Secondary Neurohormone activity Change in concentration of Angiotensin II (A II) from baseline 16 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Active, not recruiting NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
Completed NCT04549181 - Problem-Solving for Rural Heart Failure Dyads N/A